Róbert Wessman
Chairman/CEO
Alvotech
Alvotech is a global biotechnology company specializing in the development and manufacture of biosimilar medicines to broaden patient access to affordable biologic therapies. The company employs a vertically integrated approach, from cell line development through fill-finish manufacturing, and currently has five approved biosimilars on the market with nine additional candidates in development.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Updated yesterday
Funding
Raised to date
$465MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
$165M · Post-Ipo
Announced Jun 2026
Disclosed cumulative: $465M
2/2
RoundDateAmountValuationInvestors
Founders
Product
Problem
Biologic medicines are often expensive, limiting patient access despite their effectiveness in treating serious diseases. The high cost is due to the complex manufacturing processes and research required to develop these therapies.
Solution
Alvotech develops and manufactures biosimilars to increase access to more affordable biologic medicines. They employ a vertically integrated approach, managing the entire process from cell line development to fill-finish manufacturing. This strategy allows them to control quality, scale production, and accelerate the delivery of cost-competitive biosimilars to patients worldwide. The company maintains a singular focus on biosimilars while relying on strategic partners for commercialization and distribution across global markets.
Target Audience
The primary target audience includes patients who require biologic medicines but are unable to afford current market prices, as well as healthcare providers and payers seeking cost-effective treatment options.
Features
- Vertically integrated manufacturing process from cell line development to fill-finish
- Five biosimilars already approved and marketed globally, including biosimilars to Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva®
- Development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer
- State-of-the-art manufacturing facility supporting high-quality, cost-competitive production
- Network of strategic commercial partnerships providing global reach across the United States, Europe, Japan, China, and other key markets